BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26164002)

  • 1. miR-141 as potential suppressor of β-catenin in breast cancer.
    Abedi N; Mohammadi-Yeganeh S; Koochaki A; Karami F; Paryan M
    Tumour Biol; 2015 Dec; 36(12):9895-901. PubMed ID: 26164002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.
    Mohammadi-Yeganeh S; Paryan M; Arefian E; Vasei M; Ghanbarian H; Mahdian R; Karimipoor M; Soleimani M
    Tumour Biol; 2016 Jul; 37(7):8993-9000. PubMed ID: 26758430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo.
    Mohammadi-Yeganeh S; Hosseini V; Paryan M
    J Cell Physiol; 2019 Aug; 234(10):18317-18328. PubMed ID: 30945294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
    Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
    Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer.
    Razaviyan J; Hadavi R; Tavakoli R; Kamani F; Paknejad M; Mohammadi-Yeganeh S
    Appl Biochem Biotechnol; 2018 Dec; 186(4):1074-1089. PubMed ID: 29862445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WNT1 Gene from WNT Signaling Pathway Is a Direct Target of miR-122 in Hepatocellular Carcinoma.
    Ahsani Z; Mohammadi-Yeganeh S; Kia V; Karimkhanloo H; Zarghami N; Paryan M
    Appl Biochem Biotechnol; 2017 Mar; 181(3):884-897. PubMed ID: 27687586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT.
    Nie J; Jiang HC; Zhou YC; Jiang B; He WJ; Wang YF; Dong J
    Biosci Biotechnol Biochem; 2019 Jun; 83(6):1062-1071. PubMed ID: 30950326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
    Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
    BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway.
    Kong LY; Xue M; Zhang QC; Su CF
    Oncotarget; 2017 Feb; 8(9):15507-15519. PubMed ID: 28099945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
    Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
    J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.
    Song GQ; Zhao Y
    Tumour Biol; 2015 Jul; 36(7):5001-9. PubMed ID: 25680404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer.
    Phan B; Majid S; Ursu S; de Semir D; Nosrati M; Bezrookove V; Kashani-Sabet M; Dar AA
    Oncotarget; 2016 Apr; 7(15):19519-30. PubMed ID: 26799586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of miR-214 in β-catenin gene expression within hepatocellular carcinoma.
    Karimkhanloo H; Mohammadi-Yeganeh S; Hadavi R; Koochaki A; Paryan M
    Mol Biol Rep; 2020 Oct; 47(10):7429-7437. PubMed ID: 32901357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1.
    Shyamasundar S; Lim JP; Bay BH
    Int J Oncol; 2016 Dec; 49(6):2629-2636. PubMed ID: 27840899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene.
    Menbari MN; Rahimi K; Ahmadi A; Mohammadi-Yeganeh S; Elyasi A; Darvishi N; Hosseini V; Abdi M
    J Cell Physiol; 2020 Mar; 235(3):2631-2642. PubMed ID: 31508813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
    Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.